Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

NCT ID: NCT05587543

Last Updated: 2024-11-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-28
• Study Completion Date: 2030-10-31

Brief Summary

This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.

Detailed Description

Each subject was observed for at least 4 weeks after cell reinfusion (DLT observation period) . A minimum of three participants should be included in each dose group, and two or more participants should not be included in each dose group at the same time, each subject should not be enrolled until the first 1 subject did not experience a grade 3 or higher adverse event (CTCAE5.0) related to the study drug during the DLT observation period. Three or six subjects were enrolled in each dose group, depending on the occurrence of DLT. If three subjects in one dose group did not experience DLT, three subjects were enrolled in the next higher dose group; if one of three subjects experienced DLT, three more subjects were enrolled in the dose group; Expanded to 6 subjects; if only 1 of the 6 subjects after amplification produced a DLT, then 3 subjects were enrolled into the next higher dose; If a DLT occurred in ≥2 of the 6 subjects after amplification, then the dose was specified to be higher than the MTD (MTD defined as the highest dose at which a DLT occurred in ≤1/6 subjects) , new subjects were included in the previous lower dose (tolerated dose) group until the lower dose group reached 6 subjects. If DLT occurred in ≤1/6 of the subjects, the lower dose group was defined as MTD or the best effective dose. A total of six subjects received the maximum tolerated dose. In the course of the study, the researcher can combine the safety and preliminary efficacy data of the enrolled subjects, and take the safety of the subjects and the maximum benefit of the disease as the premise, study treatment was performed at the maximum tolerated dose or other doses determined by the investigator.

Conditions

Nasopharyngeal Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CAR-T

Target A positivity was assigned to CAR-T cell therapy.

Group Type: EXPERIMENTAL

PK Blood Collection

Intervention Type: BEHAVIORAL

All subjects were subjected to PK blood sampling as prescribed by the protocol.

CAR

Intervention Type: DRUG

Target A positive subjects will receive CAR-T cell therapy.

TCR-T

Target A negative, Target B positive and Target C positive were assigned to TCR-T cell treatment group.

Group Type: EXPERIMENTAL

PK Blood Collection

Intervention Type: BEHAVIORAL

All subjects were subjected to PK blood sampling as prescribed by the protocol.

TCR

Intervention Type: DRUG

Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.

Interventions

PK Blood Collection

All subjects were subjected to PK blood sampling as prescribed by the protocol.

Intervention Type: BEHAVIORAL

CAR

Target A positive subjects will receive CAR-T cell therapy.

Intervention Type: DRUG

TCR

Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.

Intervention Type: DRUG

Other Intervention Names

CAR-T cell therapy; TCR -T cell therapy

Eligibility Criteria

Inclusion Criteria

• Voluntary written informed consent;
• Age ≥18 years old, ≤75 years old, male and female;
• Expected survival ≥3 months;
• The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;
• Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish) .
• Pathological Paraffin section testing (within 5 years before signing the informed consent form) ;
• At least one measurable lesion according to RECIST v1.1 criteria for solid tumors;
• Recurrent/metastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy;
• An apheresis or venous access can be established and there are no other contraindications to blood cell isolation；
• CTCAE 5.0 was lower than grade 1 in the side effects of previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.)
• During the study period and up to 6 months after the end of the administration, fertile subjects -LRB-both male and female) were required to use effective medical contraception. For women of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the results were negative.

Exclusion Criteria

• Active central nervous system metastases (except those that are stable after treatment)；
• HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS/ml) , HCV antibody positive and HCV RNA positive;
• Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect;
• Subjects with severe autoimmune disease and long-term use of immunosuppressants;
• Active or uncontrolled infection requiring systemic therapy was present within 14 days prior to enrollment；
• Any unstable systemic disease;
• Complicated with dysfunction of important organs such as lung, brain and kidney.
• Subjects had undergone major surgery or severe trauma within 4 weeks before receiving cell therapy, or were expected to undergo major surgery during the study period.
• Participants received their last dose of radiation or anti-tumor therapy within 4 weeks of receiving the cell therapy.
• Participants had or had had other cancers that were incurable for up to 3 years, except for cervical cancer in situ or skin basal-cell carcinoma, and other cancers that had disease-free survival of more than 5 years.
• Treated with Chimeric antigen receptor t-cell therapy within six months.
• Graft-versus-host disease (GVHD)；
• Subjects who were receiving systemic steroid therapy before screening and who required long-term systemic steroid therapy during treatment as determined by the investigator (with the exception of inhaled or topical use) ; And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or topical use) .
• Severe allergies or a history of allergies;
• Subjects requiring anticoagulant therapy;
• Pregnant or lactating women, or a six-month pregnancy plan (for both men and women)；
• Researchers believe there are other reasons not to include people in treatment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Ji Dongmei

Chief Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dongmei Ji, Doctorate

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fudan University

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Dongmei Ji, Doctorate

Role: CONTACT

jidongmei2000@hotmail.com

13564183928

Facility Contacts

Dongmei Ji, doctor

Role: primary

jidongmei2000@hotmail.com

13564183928

References

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11.

Reference Type: RESULT

PMID: 25706097 (View on PubMed)

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C, Oakes CC, Alonso A, Elemento O, Pan H, Phillip JM, O'Reilly RJ, Gewurz BE, Cesarman E, Giulino-Roth L. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020 May 21;135(21):1870-1881. doi: 10.1182/blood.2019004126.

Reference Type: RESULT

PMID: 32157281 (View on PubMed)

Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16(1):87-96. doi: 10.1634/theoncologist.2010-0213. Epub 2011 Jan 6.

Reference Type: RESULT

PMID: 21212426 (View on PubMed)

Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. Pathogens. 2018 Mar 7;7(1):28. doi: 10.3390/pathogens7010028.

Reference Type: RESULT

PMID: 29518976 (View on PubMed)

Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004 Feb 1;10(3):803-21. doi: 10.1158/1078-0432.ccr-0670-3.

Reference Type: RESULT

PMID: 14871955 (View on PubMed)

Kimura H, Fujiwara S. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases. Front Pediatr. 2019 Jan 4;6:417. doi: 10.3389/fped.2018.00417. eCollection 2018.

Reference Type: RESULT

PMID: 30662890 (View on PubMed)

Healy JA, Dave SS. The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. Curr Top Microbiol Immunol. 2015;390(Pt 1):315-37. doi: 10.1007/978-3-319-22822-8_13.

Reference Type: RESULT

PMID: 26424652 (View on PubMed)

Mao Y, Zhang DW, Zhu H, Lin H, Xiong L, Cao Q, Liu Y, Li QD, Xu JR, Xu LF, Chen RJ. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol. 2012 Dec 13;7:178. doi: 10.1186/1746-1596-7-178.

Reference Type: RESULT

PMID: 23237707 (View on PubMed)

Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, Song YW, Liu YP, Fang H, Ren H, Wu RY, Chen B, Zhang XM, Lu NN, Zhou LQ, Li YX. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012 Sep 6;120(10):2003-10. doi: 10.1182/blood-2012-06-435024. Epub 2012 Jul 23.

Reference Type: RESULT

PMID: 22826562 (View on PubMed)

Cho SG, Kim N, Sohn HJ, Lee SK, Oh ST, Lee HJ, Cho HI, Yim HW, Jung SE, Park G, Oh JH, Choi BO, Kim SW, Kim SW, Chung NG, Lee JW, Hong YS, Kim TG. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs. Mol Ther. 2015 Aug;23(8):1401-1409. doi: 10.1038/mt.2015.91. Epub 2015 May 28.

Reference Type: RESULT

PMID: 26017177 (View on PubMed)

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

Reference Type: RESULT

PMID: 30207593 (View on PubMed)

Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019 Jul 6;394(10192):64-80. doi: 10.1016/S0140-6736(19)30956-0. Epub 2019 Jun 6.

Reference Type: RESULT

PMID: 31178151 (View on PubMed)

Wang L, Tian WD, Xu X, Nie B, Lu J, Liu X, Zhang B, Dong Q, Sunwoo JB, Li G, Li XP. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer. 2014 Feb 1;120(3):363-72. doi: 10.1002/cncr.28418. Epub 2013 Nov 4.

Reference Type: RESULT

PMID: 24190575 (View on PubMed)

Zhu S, Chen J, Xiong Y, Kamara S, Gu M, Tang W, Chen S, Dong H, Xue X, Zheng ZM, Zhang L. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma. PLoS Pathog. 2020 Jan 6;16(1):e1008223. doi: 10.1371/journal.ppat.1008223. eCollection 2020 Jan.

Reference Type: RESULT

PMID: 31905218 (View on PubMed)

Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31.

Reference Type: RESULT

PMID: 31150573 (View on PubMed)

Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, Chan OS, Chang AT, Yeung RM. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014 Mar;110(3):377-84. doi: 10.1016/j.radonc.2014.02.003. Epub 2014 Mar 11.

Reference Type: RESULT

PMID: 24630534 (View on PubMed)

Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012 Feb;13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7.

Reference Type: RESULT

PMID: 22154591 (View on PubMed)

Oliva M, Huang SH, Taylor R, Su J, Xu W, Hansen AR, Jang R, Bayley A, Hosni A, Giuliani M, Ringash J, Bratman SV, Cho J, Irish J, Waldron J, Weinreb I, Kim J, O'Sullivan B, Siu LL, Spreafico A. Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. Oral Oncol. 2020 Jun;105:104666. doi: 10.1016/j.oraloncology.2020.104666. Epub 2020 Apr 6.

Reference Type: RESULT

PMID: 32272384 (View on PubMed)

Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.

Reference Type: RESULT

PMID: 29329591 (View on PubMed)

Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr. Driving cars to the clinic for solid tumors. Gene Ther. 2018 Jun;25(3):165-175. doi: 10.1038/s41434-018-0007-x. Epub 2018 Jun 7.

Reference Type: RESULT

PMID: 29880908 (View on PubMed)

Other Identifiers

2207257-17

Identifier Type: -

Identifier Source: org_study_id